Press releases

TIBEAY Biosciences raises EUR 35 million for a Phase 3b trial of Ronopterin in traumatic brain injury

Hemispherian Initiates Phase 1/2a Clinical Trial of GLIX1 in Glioblastoma

Hemispherian Announces USPTO Notice of Allowance for Key GLIX1 Patent Covering Majority of Solid Tumors

BioLineRx Ltd. and Hemispherian AS Establish Joint Venture to Develop GLIX1, a First-in-Class, Oral, Small Molecule Targeting DNA Damage Response in Glioblastoma and Other Cancers

Hemispherian Receives U.S. FDA Orphan Drug Designation for GLIX1 for the Treatment of Malignant Glioma

Hemispherian receives positive opinion for Orphan Medicinal Product Designation in the EU for GLIX1 in glioma

Tagworks Pharmaceuticals Announces FDA Clearance of IND Application and Initiation of Phase 1 Clinical Trial for TGW101 and Appoints Keith Orford, MD, PhD, as Chief Medical Officer

Tagworks Pharmaceuticals Appoints Ken Mills as Chief Executive Officer

Atriva Therapeutics Announces Exclusive Letter Agreement for Reverse Takeover Transaction with Biocure Technology

Tagworks Pharmaceuticals Announces $65 Million in Series A Financing to Advance Click-to-Release Therapeutics

Atriva Therapeutics appoints Christian Pangratz as Chief Executive Officer, implementing planned management change

Hemispherian Secures EUR 10M in Financing from the European Innovation Council (EIC) Accelerator Program

Atriva Therapeutics announces Topline Results from the Proof of Concept (POC) / Phase 2a RESPIRE study (zapnometinib) in patients hospitalized with COVID-19

Xenikos Enrolls First Patient in Global Pivotal Phase 3 Study Evaluating T-Guard® in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease

Hemispherian raises seed funding for novel cancer therapeutics

Atriva Therapeutics receives U.S. FDA Orphan Drug Designation for Zapnometinib to treat Hantavirus Infections

APTAMER GROUP: ADMISSION TO TRADING ON AIM & FIRST DAY OF DEALINGS

Atriva Therapeutics strengthens advisory board with Piet Wigerinck

Atriva Therapeutics’ lead candidate Zapnometinib shows substantial efficacy against SARS-CoV-2

Xenikos Secures €40 Million in Convertible Debt Financing, Veloxis Pharmaceuticals Joins as Strategic Investor

Spahn/Karliczek: Weiterer Schub zur Entwicklung und Herstellung von versorgungsnahen Arzneimitteln gegen COVID-19